Runnymede Capital Advisors’s Eli Lilly LLY Stock Holding History

Runnymede Capital Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$602K	Buy	502 +30	+6%	+$30.7K	0.36%	39
2026 Q1	$434K	Sell	472 -1,224	-72%	-$1.24M	0.37%	45
2025 Q4	$1.82M	Buy	1,696 +1,073	+172%	+$1.03M	1.05%	27
2025 Q3	$475K	Hold	623	–	–	0.39%	43
2025 Q2	$486K	Sell	623 -30	-5%	-$23.3K	0.45%	42
2025 Q1	$539K	Sell	653 -3	-0.5%	-$2.5K	0.52%	34
2024 Q4	$506K	Buy	+656	New	+$543K	0.44%	36

Other funds holding LLY

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ONB

Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

GIM

Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

Runnymede Capital Advisors's LLY Position: Q2 2026 in Review

Runnymede Capital Advisors increased its Eli Lilly (LLY) stake by 6.4% in Q2 2026, buying an estimated $30.7K and bringing the position to 502 shares worth $602K. The position accounts for 0.36% of the portfolio, ranked #39.

Runnymede Capital Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.82M in Q4 2025. 1,233 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Runnymede Capital Advisors held 502 shares of Eli Lilly worth $602K as of Q2 2026.
Runnymede Capital Advisors bought 30 Eli Lilly shares in Q2 2026, an estimated $30.7K.
Eli Lilly made up 0.36% of Runnymede Capital Advisors's portfolio in Q2 2026, its #39 holding.
Runnymede Capital Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
Runnymede Capital Advisors's Eli Lilly position peaked at $1.82M in Q4 2025.
1,233 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Runnymede Capital Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.